---
aliases: >-
  /news/cognito-therapeutics-touts-positive-phase-2-results-for-device-delivered-alzheimers-treatment
archetype: curated-content
author:
  - Radhika Narayanan
basePath: /news/
breadcrumbLinks:
  - /
  - /news/
  - ''
breadcrumbs:
  - Home
  - News
  - >-
    Cognito Therapeutics Touts Positive Phase 2 Results For Device-Delivered
    Alzheimer's Treatment
categories:
  - 'KLAS: Oncology Treatment Planning'
categorySlug:
  - 'klas: oncology treatment planning'
categoryUrl:
  - topic/klas-oncology-treatment-planning
categoryLabel:
  - Oncology Treatment Planning
contentCategories: netspective-medigy-news-curated-content
institution: null
offering: null
layOut: single
date: '2021-03-11'
description: >-
  Yesterday Cognito Therapeutics, a startup using visual and auditory
  stimulation to treat neurodegenerative disorders, announced Phase 2 trial
  results suggesting its gamma frequency neuromodulation the
favIconImage: null
featuredImage:
  alt: >-
    Cognito Therapeutics Touts Positive Phase 2 Results For Device-Delivered
    Alzheimer's Treatment
  format: JPEG
  href: e6dcc1a1-f057-567c-b05e-3e5dafd01d2a-featuredImage.jpeg
  size:
    - 523
    - 449
  valid: true
  workPackage: 4759
  wpAttachment:
    fileName: Curated_Featured_Image.jpg
    link: /api/v3/attachments/11135/content
featuredPdf: null
htmlMetaData:
  author: null
  description: null
  generator: null
  viewport: null
  articlemodified_time: null
  articlepublished_time: null
  msvalidate.01: null
  ogdescription: null
  ogimage: null
  ogsite_name: null
  ogtitle: null
  ogtype: null
  ogupdated_time: null
  ogurl: null
  yandex-verification: null
  robots: null
  fbapp_id: null
  oglocale: null
  fbadmins: null
  articlepublisher: null
  google-site-verification: null
  keywords: null
id: 4759
identifier: News
lastMod: '2021-03-11T12:59:12.005048Z'
link:
  brand: mobihealthnews.com
  href: >-
    https://www.mobihealthnews.com/news/cognito-therapeutics-touts-positive-phase-2-results-device-delivered-alzheimers-treatment
  original: >-
    https://www.mobihealthnews.com/news/cognito-therapeutics-touts-positive-phase-2-results-device-delivered-alzheimers-treatment
href: >-
  https://www.mobihealthnews.com/news/cognito-therapeutics-touts-positive-phase-2-results-device-delivered-alzheimers-treatment
original: >-
  https://www.mobihealthnews.com/news/cognito-therapeutics-touts-positive-phase-2-results-device-delivered-alzheimers-treatment
mastHead: NEWS
mdName: e6dcc1a1-f057-567c-b05e-3e5dafd01d2a.md
openGraphMetaData:
  ogdescription: null
  ogtitle: null
  ogurl: null
  ogimage: null
  ogsite_name: null
  ogtype: null
  ogupdated_time: null
  ogimageheight: null
openProjectCustomFields:
  cleanUrl: >-
    https://www.mobihealthnews.com/news/cognito-therapeutics-touts-positive-phase-2-results-device-delivered-alzheimers-treatment
  medigyTopics:
    - 'KLAS: Oncology Treatment Planning'
  sourceUrl: >-
    https://www.mobihealthnews.com/news/cognito-therapeutics-touts-positive-phase-2-results-device-delivered-alzheimers-treatment
openProjectWorkPackageType: Curated Content
searchCategory: News
slug: >-
  mobihealthnews-cognito-therapeutics-touts-positive-phase-2-results-for-device-delivered-alzheimers-treatment
source: open-project-curations
status: ''
sub: brief
tags:
  - News
title: >-
  Cognito Therapeutics Touts Positive Phase 2 Results For Device-Delivered
  Alzheimer's Treatment
via: ' '
insights_description: null
insights_name: null
viaLink: null
relatedOfferings:
  - label: Thynk Health’s Lung Cancer Screening Solution
    permalink: /offering/thynk-healths-lung-cancer-screening-solution
    categories:
      - 'KLAS: Oncology Treatment Planning'
      - 'Healthcare IT News: Electronic Patient Record (EPR)'
    offeringId: 6802
  - label: Oleena®
    permalink: /offering/oleena-r
    categories:
      - 'KLAS: Oncology Treatment Planning'
      - 'Healthcare IT News: Remote Patient Monitoring'
      - 'Symplur: Digital Therapeutics'
    offeringId: 6401
twitterMetaData:
  twittercard: null
  twitterdescription: null
  twittertitle: null
  twitterimage: null
  twitterurl: null
---
<p>Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation therapy slowed declines in memory and&nbsp;cognition among mild-to-moderate Alzheimer's disease patients.</p><p>The <a href="https://clinicaltrials.gov/ct2/show/NCT03556280">OVERTURE study</a>, a multi-center, randomized controlled trial, enrolled 76 such patients aged 50 years or older beginning in 2018. These participants were randomized to receive either Cognito's audio-visual stimulation treatment or a sham stimulation for one hour each day&nbsp;in their home.</p><p>Throughout the six-month treatment period, Cognito said the treatment group (n = 33) compared to the placebo group (n =20) demonstrated a significant 84% slowdown in functional decline and a significant 83% decline in cognitive impairment, as measured using standardized scales every four weeks. In addition, there was a significant&nbsp;61% reduction in whole brain atrophy and volumetric loss among 30 treatment group participants in comparison to 19 placebo group participants, according to the company.</p>